We understand that it can be challenging to gain clarity and perspective on breaking Parkinson's news. Q&As in this section are conducted with leading experts in the Parkinson's disease research field to quickly provide an informed, impartial opinion on new findings -- and to get to the bottom of what they might mean for researchers and people living with PD today.
August 11, 2010
Yesterday, two major news stories broke on the pursuit of biomarkers for neurodegenerative disease. One of the articles appeared in The New York Times and the other appeared in The Wall Street Journal. The Alzheimer's Disease Neuroimaging Initiative (ADNI), a multi-year clinical study, reported a simple and practical test to accurately predict who will develop Alzheimer's. Additionally, Parkinson's scientists reported leveraging Alzheimer's research to better understand the cognitive impairment ...Read More
July 30, 2010
Medical experts are proposing new criteria for Alzheimer's disease to help diagnose patients earlier, according to a recent New York Times article. The criteria are based on new tools that may be able to detect the disease in the brain, blood or spinal fluid even before there are symptoms. These new tools, called biomarkers, are also being developed for Parkinson's disease to help diagnose the disease and track its progression. Biomarkers will also help drug developers determine whether a potent...Read More
July 14, 2010
A new study published in the June issue of Science Translational Medicine reports that an excess of serotonin cells in the tissue transplants used over a decade ago in experimental treatments for PD may be responsible for the onset of dyskinesias, the involuntary movements that are usually associated with dopamine replacement therapy.
The Michael J. Fox Foundation spoke with one of the study authors, Anders Björklund, MD, PhD, of Lund University to learn more about the role of serotonin in dyski...
June 21, 2010
A study published in the June issue of the Archives of Neurology found that men with certain variations in a gene called ABCB1 who were exposed to high levels of toxic pesticides were three and a half times more likely to develop Parkinson's disease than those with the normal version of the gene. The pesticides that were assessed in the study belong to a class called organochlorines, which includes DDT.
The Michael J. Fox Foundation spoke with Jason R. Richardson MS, PhD of the Robert Wood Johns...
June 08, 2010
(This Q&A is an update to a May 2010 MJFF News in Context with Dr. Bronstein.)
On June 3, 2010, The New England Journal of Medicine published the results from the largest, randomized, controlled study of deep brain stimulation (DBS) for advanced Parkinson's disease. The study found that DBS at two different targets, the subthalamic nucleus (STN) and the globus pallidus interna (GPi), produces similar motor and quality of life improvements for Parkinson's patients.
The Michael J. Fox Foundation sp...